Traditionelle Definitionen sind unscharf gefasst - Definition und Diagnose der Sepsis nach aktuellen Kriterien

Zusammenfassung

Die mikrobiologische Diagnose der Sepsis ist zeitintensiv und häufig nicht möglich. Auffällige Merkmale der meisten klinischen Studien sind die Unklarheit und Inkonstanz der verwendeten klinischen und mikrobiologischen Definitionen. Das Fehlen valider epidemiologischer Daten zu Inzidenz, Prävalenz, Letalität und Verlauf steht im Kontrast zu der großen gesundheitsökonomischen Bedeutung der Sepsis. Die Diagnose erfolgt in der Regel zu spät, weil es gegenwärtig keine angemessenen Mittel gibt, den Übergang einer lokal begrenzten Infektion zu einer schweren Sepsis vorherzusagen. Inflammatorische Marker spielen für die Diagnostik der Sepsis und deren Verlaufskontrolle eine zunehmende Rolle, da die Spezifität klinischer Symptome und klassischer Infektionszeichen (Temperaturerhöhung oder -erniedrigung, Leukozytose, Thrombozytenabfall) gering ist. Die Anzahl und das Ausmaß der assoziierten Organdysfunktion(en) beeinflussen den Verlauf und die Mortalität der Sepsis wesentlich. Neue Marker wie das Prohormon Procalcitonin korrelieren besser mit dem Schweregrad der Sepsis als bisher verfügbare Messgrößen. Sie erleichtern daher, neben den klinischen Zeichen des Syndroms, die Diagnose und Verlaufsbeurteilung der Sepsis.

Summary

The term „sepsis” has long been used interchangeably with bacteremia, septicemia or severe sepsis, thereby causing confusion in interpreting epidemiological data. Due to major weaknesses in the ICD-10 terminology, sepsis is mostly not accurately coded on hospital charts, which accounts to the low public awareness of this disease. Early diagnosis of the different severities of infectious-induced inflammation is important for early implementation of specific therapies. Sepsis and severe sepsis are accompanied by clinical and laboratory signs of systemic inflammation. However, patients suffering from non-infectious inflammation may present with similiar signs and symptoms making it difficult to diagnose infection based on clinical findings alone. Microbiological evidence of sepsis, though definitive and specific, may not be obtainable, is time-consuming and even may not occur concurrently with clinical signs of sepsis. It is therefore important to identify markers, which by enabling an early diagnosis of sepsis, would allow early therapeutic interventions. Whereas C-reactive protein is a more sensitive parameter for the diagnosis of localized infections outside the intensive care unit, procalcitonin is currently the most useful parameter to improve the diagnosis and monitoring of therapy in critically ill patients with severe sepsis and septic shock.

sepsis - severe sepsis - septic shock - definition - diagnosis - ICD-10 - ACCP/SCCM consensus conference criteria - marker - procalcitonin

Literatur

• 1 Angus DC, Linde-Zwirble WT, Lidicker J. et al. . Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care.  Crit Care Med. 2001;  29 1303-1310
• 2 Bernard GR, Vincent JL, Laterre PF. Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. . Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 699-709
• 3 Bone RC. Let's agree on terminology: definitions of sepsis.  Crit Care Med. 1991;  19 973-976
• 4 Bone RC, Fisher Jr CJ, Clemmer TP. et al. . Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group.  Crit Care Med. 1989;  17 389-393
• 5 Brun-Buisson C, Doyon F, Carlet J. et al. . Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis.  JAMA. 1995;  274 968-974
• 6 Brunkhorst FM, Eberhard OK, Brunkhorst R. Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin.  Crit Care Med. 1999;  27 2172-2176
• 7 Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock.  Intensive Care Med. 2000;  26 148-152
• 8 Dandona P, Nix D, Wilson MF. et al. . Procalcitonin increase after endotoxin injection in normal subjects.  J Clin Endocrinol Metab. 1994;  79 1605-1608
• 9 Gramm HJ, Hannemann L, Reinhart K, Lode H. Sepsis: ein Begriff im Wandel. Möglichkeiten und Grenzen der Diagnose anhand klinischer Kriterien.  Dtsch Med Wochenschr. 1995;  120 498-502
• 10 Harbarth S, Holeckova K, Froidevaux C. et al. . Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.  Am J Respir Crit Care Med. 2001;  164 396-402
• 11 Hotchkiss RS. The pathophysiology and treatment of sepsis.  New Engl J Med. 2003;  348 138-150
• 12 Levy MM, Fink MP, Marshall JC. International Sepsis Definitions Conference, 2001. . SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.  Intensive Care Med. 2003;  29 530-538
• 13 Linde-Zwirble W. et al. . The confusion between septicemia and severe sepsis.  Value in Health. 2001;  4 60
• 14 Lundberg JS, Perl TM, Wiblin T. et al. . Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units.  Crit Care Med. 1998;  26 1020-1024
• 15 Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000.  N Engl J Med. 2003;  348 1546-1554
• 16 Meisner M. Procalcitonin. A new, innovative infection parameter (3rd ed).  Stuttgart: Georg Thieme Verlag. 2000; 
• 17 Meisner M, Tschaikowsky K, Schnabel S. et al. . Procalcitonin: Influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations.  Eur J Clin Chem Clin Biochem. 1997;  35 597-601
• 18 Members of the American College of Chest Physicians / Society of Critical Care Medicine Consensus Conference Committee . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.  Crit Care Med. 1992;  20 864-874
• 19 Moerer O, Schmid A, Hofmann M. et al. . Direct costs of severe sepsis in three german intensive care units based on a retrospective electronic patient record analysis of resource use.  Intensive Care Med. 2002;  28 1440-1446
• 20 Müller B, Becker KL, Schächinger H. et al. . Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit.  Crit Care Med. 2000;  28 977-983
• 21 Niedermann FS, Fein AM. Sepsis syndrome, the adult respiratory distress syndrome and nosocomial pneumonia: a common clinical consequence.  Clin Chest Med. 1990;  11 633-656
• 22 Oberhoffer M, Karzai W, Meier-Hellmann A. et al. . Sensitivity and specifity of various markers of inflammation for the prediction of tumor necrosis factor alpha and interleukin-6 in patients with sepsis.  Crit Care Med. 1999;  27 1814-1818
• 23 Ollendorf DA, Fendrick AM, Massey K. et al. . Is sepsis accurately coded on hospital bills?.  Value in Health. 2002;  5 79-81
• 24 Panacek E. et al. . Neutralization of the TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: results of the monarcs trial.  Chest. 2000;  118 88
• 25 Parillo JE, Parker MM, Natanson C. et al. . Septic shock in humans: advances in understanding of pathogenesis, cardiovascular dysfunction, and therapy.  Ann Int Med. 1990;  113 227-242
• 26 Rangel-Frausto M. The epidemiology of bacterial sepsis.  Infect Dis Clin North Am. 1999;  13 299-312
• 27 Rangel-Frausto MS, Pittet D, Costigan M. et al. . The natural history of the systemic inflammatory response syndrome (SIRS) A prospective study.  JAMA. 1995;  273 117-123
• 28 Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia.  Clin Microbiol Rev. 1997;  10 444-465
• 29 Reyes WJ, Brimioulle S, Vincent J-L. Septic shock without documented infection: an uncommon entity with a high mortality.  Intensive Care Med. 1999;  25 1267-1270
• 30 Rychlik R, Pfeil B. Sozioökonomische Relevanz der Sepsis in Deutschland.  Gesundh Ökon Qual Manag. 2000;  5 67-72
• 31 Schmid A, Burchardi H, Clouth J. et al. . Burden of illness imposed by severe sepsis in Germany.  Eur J Health Econom. 2002;  3 77-82
• 32 Sepsis . a study of doctor's knowledge about sepsis in five European countries and the US.  ESICM and SCCM.. 2001; 
• 33 Ugarte H, Silva E, Mercan D. et al. . Procalcitonin used as a marker in the intensive care unit.  Crit Care Med. 1999;  27 498-504
• 34 Wakefield CH, Barclay GR, Fearon KC. et al. . Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra-abdominal sepsis.  Scottish Sepsis Intervention Group. Brit J Surg. 1998;  85 818-825

1 Tumor, Nodi, Metastasen

2 monoclonal antibody improves survival and reduces organ dysfunction in human sepsis

3 recombinant human activated protein C worldwide evaluation in severe sepsis

Anschrift des Verfassers